Gilead Sciences, Inc. announced on May 12, 2023, that it has acquired all outstanding shares of XinThera, a San Diego-based private biotech company. The acquisition will complement Gilead's existing clinical development priorities by adding pipeline assets for well-validated targets in oncology and inflammation.
The research resources of XinThera have the potential to target the DNA damage repair pathway in the treatment of cancer and to control the immune response in the treatment of inflammatory diseases, which may lead to better outcomes for patients with these diseases.
According to Flavius Martin, M.D., executive vice president of research at Gilead Sciences, the XinThera team has created best-in-class small molecule drugs for the treatment of cancer and immunologic conditions.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved medical breakthroughs for over three decades, with the aim of making the world healthier for everyone. The acquisition of XinThera is a strategic move to strengthen Gilead's early pipeline in oncology and inflammation, two areas where the company already has a strong presence.
Oncology is a major area of focus for Gilead Sciences, with several oncology products already on the market. The company's current oncology portfolio includes Yescarta, a CAR T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Trodelvy, a treatment for metastatic triple-negative breast cancer; and Zydelig, a treatment for certain types of blood cancers.
Inflammation is another therapeutic area where Gilead Sciences has established itself as a leader. The company's current portfolio includes filgotinib, a JAK inhibitor for the treatment of rheumatoid arthritis, and selonsertib, an investigational therapy for the treatment of liver fibrosis.
The acquisition of XinThera will add to Gilead's existing pipeline in oncology and inflammation, providing the company with additional promising compounds for the treatment of these diseases. This will enable Gilead to continue to deliver on its commitment to developing breakthrough therapies for patients in need.
Gilead Sciences' acquisition of XinThera is a strategic move to strengthen its early pipeline in oncology and inflammation. The addition of XinThera's pipeline assets will complement Gilead's existing clinical development priorities and provide the company with additional promising compounds for the treatment of cancer and inflammatory diseases.
With a strong track record of breakthroughs in medicine, Gilead Sciences is well-positioned to continue delivering innovative therapies that make a meaningful difference in the lives of patients.
